Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC, van Koetsveld PM, Feelders RA, de Herder WW, Dogan F, Janssen JAMJL, Hofste Op Bruinink D, Pivonello C, Waaijers AM, Colao A, de Krijger RR, Pivonello R, Hofland LJ. De Martino MC, et al. Among authors: hofste op bruinink d. Endocrine. 2019 Jun;64(3):673-684. doi: 10.1007/s12020-019-01869-1. Epub 2019 Mar 5. Endocrine. 2019. PMID: 30838516 Free PMC article.
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste Op Bruinink D, Hoogenboezem R, Sanders MA, van de Woestijne PC, Bos PK, Khandanpour C, Vermeulen J, Moreau P, van Duin M, Broijl A, Sonneveld P, Cupedo T. de Jong MME, et al. Among authors: hofste op bruinink d. Nat Immunol. 2021 Jun;22(6):769-780. doi: 10.1038/s41590-021-00931-3. Epub 2021 May 20. Nat Immunol. 2021. PMID: 34017122 Clinical Trial.
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P. Hofste Op Bruinink D, et al. J Clin Oncol. 2022 Sep 20;40(27):3132-3150. doi: 10.1200/JCO.21.01217. Epub 2022 Mar 31. J Clin Oncol. 2022. PMID: 35357885 Free PMC article.
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.
Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. Misund K, et al. Among authors: hofste op bruinink d. Leukemia. 2022 Jul;36(7):1887-1897. doi: 10.1038/s41375-022-01597-y. Epub 2022 May 28. Leukemia. 2022. PMID: 35643867 Free PMC article.
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Hofste op Bruinink D, Oliva S, Rihova L, Schmitz A, Gilestro M, Te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, Van der Velden VHJ. Hofste op Bruinink D, et al. Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831. Haematologica. 2020. PMID: 33054135 Free PMC article. No abstract available.